EUVIMEDEUVIMED entdecken
Crossref

Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction

Yayun Ling

Cardiovascular Reviews · 2024

DOI: 10.26689/cr.v2i1.6583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Reviews, 2024. Verfasst von Yayun Ling.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myocardial infarction has become a serious disease that affects the quality of contemporary human survival, and improved efficacy and risk avoidance can be achieved through the upgrading of thrombolytic drugs and precise intervention. This article takes the development of three generations of thrombolytic drugs as the main line, and combs through the development of thrombolytic drugs from the era of urokinase and streptokinase to Alteplase and single-chain urokinase-type fibrinogen activator and their respective advantages and disadvantages. The advantages of three generations of tissue-type fibrinogen kinase derivatives, Reteplase, and tenecteplase, are compared and described in this article.

Zitieren

APA

Ling, Y. (2024). Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction. Cardiovascular Reviews. https://doi.org/10.26689/cr.v2i1.6583

Vancouver

Ling Y. Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction. Cardiovascular Reviews. 2024. doi:10.26689/cr.v2i1.6583

BibTeX
@article{Ling2024,
  author = {Ling, Yayun},
  title = {Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction},
  journal = {Cardiovascular Reviews},
  year = {2024},
  doi = {10.26689/cr.v2i1.6583}
}
Kostenlos starten →